EXCLUSIVE LICENSE AGREEMENT



      In this Agreement, Interleukin Genetics, Inc., a Delaware Corporation

having its principal office at 135 Beaver Street, Waltham, MA 02452 (hereafter

"IG"), and Access Business Group International LLC, having offices at 7575

Fulton Street, East, Ada, Michigan 49355-0001 (hereafter "ABG"), agree as

follows:



                             Article I - Background



      1.1 IG has developed technology relating to analyzing the effect of

variations in genes related to inflammation, including but not limited to the

effect of such variations on the risk for [ * ] and [ * ] disease, and

determining through genetic profiling, individuals who may benefit from specific

interventions to promote health, and owns the patents and patent applications

listed in Exhibit A hereto which disclose and claim certain aspects of the

technology.



      1.2 ABG desires an exclusive license under the patents, patent

applications, and technology and know-how in accordance with the terms of this

Agreement and IG is willing to grant such a license.



      1.3 ABG and IG have entered into a Research Agreement of even date with

this Agreement.



                            Article II - Definitions



      2.1   "[     *     ] Test" means an analytic test performed on a [

*     *     ] or [     *     ] to [ *     *     ] response to the use of a

Dermagenomics Consumable or a Nutrigenomics Consumable.



      2.2 "Control" or "Controlled" means (a) with respect to Technology (other

than Proprietary Materials) and/or Patent Rights, the possession by a party of

the ability to grant a license or sublicense of such Technology and/or Patent

Rights as provided herein without violating the terms of any agreement or

arrangement between such party and any third party and (b) with respect to

Proprietary Materials, the possession by a party of the ability to supply such

Proprietary Materials to the other party as provided herein without violating

the terms of any agreement or arrangement between such party and any third

party.



      2.3 "Dermagenomics Consumable" means any nutritional supplement or skin

care product or topical delivery system which [ * * * * ] designed to produce a

positive health benefit and/or a positive appearance of skin (i) the

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC